JQ-1 carboxylic acid

Name: JQ-1 carboxylic acid
Brand: MedChemExpress
SKU: HY-78695
Rating: 5.0 (9 reviews)

Cat. No.: HY-78695 Purity: 99.69%: Data Sheet
COA

SDS
Handling Instructions
FAQs
Technical Support

JQ-1 carboxylic acid, a (+)-JQ-1 (HY-13030) derivative, is a potent BET bromodomain inhibitor. JQ-1 carboxylic acid can be used to synthesize PROTAC, which can target the degradation of BRD4.

For research use only. We do not sell to patients.

CAS No. : 202592-23-2

Size	Stock	Quantity

Free Sample (0.1 - 0.2 mg)	Apply Now
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO ready for reconstitution	In-stock	Estimated Time of Arrival: December 31
Solution
10 mM * 1 mL in DMSO	In-stock	Estimated Time of Arrival: December 31
Solid
5 mg	In-stock	Estimated Time of Arrival: December 31
10 mg	In-stock	Estimated Time of Arrival: December 31
50 mg	In-stock	Estimated Time of Arrival: December 31
100 mg	In-stock	Estimated Time of Arrival: December 31
200 mg	In-stock	Estimated Time of Arrival: December 31
500 mg	In-stock	Estimated Time of Arrival: December 31
1 g	Get quote
5 g	Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 9 publication(s) in Google Scholar

Other Forms of JQ-1 carboxylic acid:

(+)-JQ-1 In-stock
(R)-(-)-JQ1 Enantiomer In-stock

9 Publications Citing Use of MCE JQ-1 carboxylic acid

RT-PCR

: JQ-1 carboxylic acid purchased from MedChemExpress. Usage Cited in: Int J Oral Sci. 2024 Jul 1;16(1):47. [Abstract]; CAL27 and HN13 cells were pretreated with JQ-1 carboxylic acid (JQ-1) for 1 h followed by stimulation with epiregulin for 24 h. The levels of PDL1 and c-Myc were examined by Western blot analysis.

: JQ-1 carboxylic acid purchased from MedChemExpress. Usage Cited in: Int J Oral Sci. 2024 Jul 1;16(1):47. [Abstract]; CAL27 and HN4 cells were pretreated with JQ-1 carboxylic acid (JQ-1) for 1 h followed by stimulation with epiregulin for 24 h. The levels of PDL1 and c-Myc were examined by Western blot analysis.

: JQ-1 carboxylic acid purchased from MedChemExpress. Usage Cited in: Int J Oral Sci. 2024 Jul 1;16(1):47. [Abstract]; HN30 cells were treated with JQ-1 carboxylic acid (JQ-1) for 24 h, and the levels of PDL1 and c-Myc were examined by Western blot analysis

: JQ-1 carboxylic acid purchased from MedChemExpress. Usage Cited in: Biochem Pharmacol. 2023 Apr:210:115497. [Abstract]; The LX2 cells were pretreated with gradient concentrations (μM) of JQ-1 carboxylic acid (JQ1; 0-100 μM) and DMSO (0.1%) for 2 h and then stimulated with TGFβ for 24 h, and the mRNA levels of αSMA and COLI were detected.

: JQ-1 carboxylic acid purchased from MedChemExpress. Usage Cited in: Biochem Pharmacol. 2023 Apr:210:115497. [Abstract]; Fibrosis-related protein expressions after treatment with JQ-1 carboxylic acid (JQ1; 1 μM) in LX2 cells.

: JQ-1 carboxylic acid purchased from MedChemExpress. Usage Cited in: Biochem Pharmacol. 2023 Apr:210:115497. [Abstract]; The mRNA and protein expressions of PLK1 with JQ-1 carboxylic acid (JQ1; 1 μM) treatment as detected by qRT-PCR and western blot in TGFβ-activated LX2 cells.

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

Biological Activity
Purity & Documentation
References
Customer Review

Description

JQ-1 carboxylic acid, a (+)-JQ-1 (HY-13030) derivative, is a potent BET bromodomain inhibitor. JQ-1 carboxylic acid can be used to synthesize PROTAC, which can target the degradation of BRD4.

IC₅₀ & Target^[1]

BET

BRD4

DCAF1

Cellular Effect

Cell Line	Type	Value	Description	References
HEK293	EC₅₀	> 50 μM Compound: JQ1-CO2H	Cytotoxicity against human HEK293 cells assessed as inhibition of cell viability incubated for 30 mins by cell titer-glo assay Cytotoxicity against human HEK293 cells assessed as inhibition of cell viability incubated for 30 mins by cell titer-glo assay	[PMID: 35859867]
HEK293	IC₅₀	> 50 μM Compound: JQ1-CO2H	Cytotoxicity against human HEK293 cells assessed as inhibition of cell viability incubated for 30 mins in presence of CRBN-tracer by nanoBRET assay Cytotoxicity against human HEK293 cells assessed as inhibition of cell viability incubated for 30 mins in presence of CRBN-tracer by nanoBRET assay	[PMID: 35859867]
HEK293	IC₅₀	> 50 μM Compound: JQ1-CO2H	Cytotoxicity against permeabilized HEK293 cells assessed as inhibition of cell viability incubated for 30 mins in presence of CRBN-tracer by nanoBRET assay Cytotoxicity against permeabilized HEK293 cells assessed as inhibition of cell viability incubated for 30 mins in presence of CRBN-tracer by nanoBRET assay	[PMID: 35859867]

In Vitro

JQ-1 carboxylic acid downregulates PD-L1 expression on the surface of B16F10 cells^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Molecular Weight

400.88

Formula

C₁₉H₁₇ClN₄O₂S

CAS No.

202592-23-2

Appearance

Solid

Color

Off-white to yellow

SMILES

ClC1=CC=C(C(C2=C(N3C4=NN=C3C)SC(C)=C2C)=N[C@H]4CC(O)=O)C=C1

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

Solvent & Solubility

In Vitro:

DMSO : 100 mg/mL (249.45 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	2.4945 mL	12.4726 mL	24.9451 mL
5 mM	0.4989 mL	2.4945 mL	4.9890 mL
10 mM	0.2495 mL	1.2473 mL	2.4945 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.08 mg/mL (5.19 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.08 mg/mL (5.19 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil
Solubility: ≥ 2.08 mg/mL (5.19 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

DMSO +

Tween-80 +

Saline

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Calculation results:

Working solution concentration: mg/mL

Method for preparing stock solution: mg drug dissolved in μL DMSO (Stock solution concentration: mg/mL).

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).

Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.

If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.

Purity & Documentation

Purity: 99.69%

Select Batch:

Data Sheet (281 KB) SDS (396 KB)

COA (259 KB) HNMR (170 KB) RP-HPLC (245 KB) MS (175 KB)

Handling Instructions (2659 KB)

References

[1]. Huang Y, et, al. Design, Synthesis, and Evaluation of Trivalent PROTACs Having a Functionalization Site with Controlled Orientation. Bioconjug Chem. 2022 Jan 19;33(1):142-151. [Content Brief]

[2]. Chen W, et, al. Dual drugs decorated bacteria irradiate deep hypoxic tumor and arouse strong immune responses. Biomaterials. 2022 Jul;286:121582. [Content Brief]

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	2.4945 mL	12.4726 mL	24.9451 mL	62.3628 mL
	5 mM	0.4989 mL	2.4945 mL	4.9890 mL	12.4726 mL
	10 mM	0.2495 mL	1.2473 mL	2.4945 mL	6.2363 mL
	15 mM	0.1663 mL	0.8315 mL	1.6630 mL	4.1575 mL
	20 mM	0.1247 mL	0.6236 mL	1.2473 mL	3.1181 mL
	25 mM	0.0998 mL	0.4989 mL	0.9978 mL	2.4945 mL
	30 mM	0.0832 mL	0.4158 mL	0.8315 mL	2.0788 mL
	40 mM	0.0624 mL	0.3118 mL	0.6236 mL	1.5591 mL
	50 mM	0.0499 mL	0.2495 mL	0.4989 mL	1.2473 mL
	60 mM	0.0416 mL	0.2079 mL	0.4158 mL	1.0394 mL
	80 mM	0.0312 mL	0.1559 mL	0.3118 mL	0.7795 mL
	100 mM	0.0249 mL	0.1247 mL	0.2495 mL	0.6236 mL